Author

R. Gargini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

B. Segura-Collar· 4 shared P. Sanchez-Gomez· 4 shared A. Hernandez-Lain· 3 shared A. Perez-Nunez· 3 shared B. Herranz· 3 shared J. M. Sepulveda-Sanchez· 3 shared D. Garcia-Perez· 2 shared A. Ayuso-Sacido· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

B. Segura-Collar

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

On optimal temozolomide scheduling for slowly growing gliomas

B. Segura-Collar, J. Jimenez-Sanchez, R. Gargini, M. Dragoj, J. M. Sepulveda, M. Pesic, P. Sanchez-Gomez, V. M. Perez-Garcia

This study uses in-silico models and experimental data to show that longer TMZ dose intervals improve survival and reduce toxicity in slowly growing gliomas by altering tumor phenotype.

bioRxiv · Mar 10, 2022 · PreprintCancer Biology

The genetic status of IDH1/2 and EGFR dictates the vascular landscape and the progression of gliomas

B. Segura-Collar, M. Garranzo-Asensio, B. Herranz, E. Hernandez-SanMiguel, B. S. Casas, A. Matheu, A. Perez-Nunez, J. M. Sepulveda-Sanchez, A. Hernandez-Lain, V. Palma, R. Gargini, P. Sanchez-Gomez

This study investigates how IDH1/2 and EGFR genetic mutations influence vascular characteristics and progression in gliomas, identifying distinct vascular phenotypes and therapeutic vulnerabilities.

bioRxiv · Sep 21, 2020 · PreprintCancer Biology

Immune profiling of gliomas reveals a connection with Tau function and the tumor vasculature.

P. Sanchez-Gomez, J. M. Sepulveda-Sanchez, T. Cejalvo, A. Hernandez-Lain, R. Gargini, B. Segura-Collar, P. Mata-Martinez, B. Herranz, D. Cantero, Y. Ruano, D. Garcia-Perez, A. Perez-Nunez, A. Ramos, M. C. Martin-Soberon

The paper profiles immune cells in gliomas, identifying two immune profiles in IDH1/2 wild-type tumors and linking immune content to vascular alterations and Tau expression.

bioRxiv · Jul 17, 2020Cancer Biology

IDH-Tau-EGFR triad defines the neovascular landscape of diffuse gliomas by controlling mesenchymal differentiation

R. Gargini, B. Segura-Collar, V. Garcia-Escudero, A. Romero-Bravo, B. Herranz, F. J. Nunez, D. Garcia-Perez, A. Ayuso-Sacido, J. Seoane, J. M. Sepulveda-Sanchez, A. Hernandez-Lain, M. G. Castro, R. Garcia-Escudero, J. Avila, P. Sanchez-Gomez, , A. Perez-Nunez

This study identifies the IDH-Tau-EGFR triad as a key factor in defining the neovascular landscape of diffuse gliomas by regulating mesenchymal differentiation and vascular microenvironment.

bioRxiv · Oct 3, 2019Cancer Biology